Compare Ascendis Pharma A/S (ASND) vs Herbalife Nutrition Ltd (HLF) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Herbalife (HLF) trades at $13.15, up 1.94% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains stable revenue around $5B annually with improving debt metrics, though negative shareholder equity remains a concern. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, supported by strong international growth and successful $1.45B debt refinancing completed in April 2026.

HLF presents a value opportunity with low P/E (5.77) and P/S (0.27) ratios, but faces significant leverage risks and competitive pressures. Analyst sentiment leans bullish (58% buy ratings) despite technical weakness, with the stock's direction likely dependent on Q2 2026 results announcement scheduled for August 5, 2026.